Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07442526
Active, not recruiting Observational

AGECTO Study: PCI vs. Optimal Medical Therapy for CTO in the Octogenarian Patients

NCT07442526 · tracked via the Priya Life Science Italy tracker
Sponsor
San Luigi Gonzaga Hospital
Phase
Observational
Started
2025-07-01
Last updated
2026-03-02

Condition(s) studied

Coronary Artery Disease (CAD)Chronic Total Occlusion (CTO)Percutaneous Coronary Intervention (PCI)Optimal Medical Therapy

Study summary

The study compares an interventional strategy (PCI) with optimal medical therapy (OMT) in ultra-octogenarians with chronic total occlusions (CTO).

Results suggest that successful PCI leads to significant improvements in symptoms and quality of life compared to OMT alone. While initially carrying higher procedural risks, CTO-PCI is considered feasible and safe in experienced centers. There is also potential for long-term benefits in survival and a reduction in major adverse cardiovascular events (MACE). The choice between treatments depends on an individual risk-benefit assessment, considering the patient's overall condition.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 80 years. * CTO in at least one major coronary artery. * Complete revascularization or non-critical stenosis in the non-CTO vessels. * Life expectancy \> 1-year Exclusion Criteria: * Severe non-cardiac comorbidities with a life expectancy \< 1 year. * CTOs in the native vessel and patency grafts in CABG patients * CTOs in the minor vessel (Non dominant RCA, small diagonal or obtuse marginal branch) * Lack of any anatomical or clinical details of the patient

Primary outcome measure(s)

  • MACE (Major Cardiovascular Events) — From enrollment to 1-year
    MACE is defined as a composite of all-cause mortality, non-fatal myocardial infarction, and repeat revascularization.

Trial sites (1)

FacilityCityRegionStatus
Rivoli Hospital Rivoli Italy

More San Luigi Gonzaga Hospital trials in Italy

Minicrush Versus Culotte Stenting in Complex Coronary Bifurcation Lesions:The Multicenter T-REX II Registry Enrolling by invitation
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis Recruiting
Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation Starting soon
Anastomotic Leakage After Right Hemicolectomy for Cancer, a Prospective Multicenter Study of SICO-CC Network Recruiting

Other trials for the same condition

Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry. Starting soon
Minicrush Versus Culotte Stenting in Complex Coronary Bifurcation Lesions:The Multicenter T-REX II Registry Enrolling by invitation
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Recruiting
The 3D Stent Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07442526 on ClinicalTrials.gov ↗ ← All trials in Italy